ID4 Rabbit Polyclonal Antibody for WB, ELISA - P47928

Core Product Specifications and Parameters

Biological Background: ID4 Function and Localization

• ID4 (Inhibitor of DNA binding 4) is a member of the inhibitor of DNA binding (ID) family, characterized by the absence of a basic DNA-binding domain, functioning as a dominant-negative regulator of basic helix-loop-helix (bHLH) transcription factors.
• As a transcriptional regulator, ID4 forms heterodimers with bHLH proteins, preventing their DNA binding and inhibiting transcriptional activity.
• ID4 is implicated in the regulation of diverse cellular processes, including cell growth, senescence, differentiation, apoptosis, angiogenesis, and neoplastic transformation (By similarity).
• The protein is predominantly localized to the nucleus, consistent with its role in transcriptional control.
• Alternative names include Class B basic helix-loop-helix protein 27 (bHLHb27) and Inhibitor of differentiation 4.
• UniProt keywords for ID4 comprise Nucleus, Repressor, Transcription, and Transcription regulation, underscoring its functional repertoire.

Experimental Guidance and Technical Tips

• The immunogen is a synthetic peptide corresponding to the N-terminal region (aa 1–100) of human ID4; for Western blot and ELISA, consider optimizing antibody dilution based on target abundance in your sample.
• Given the predicted molecular weight of approximately 17 kDa (human), confirm band specificity using appropriate positive and negative controls in WB.
• This is a polyclonal antibody; lot-to-lot consistency may vary, and validation in your specific assay system is recommended.
• Reported cross-reactivity with mouse and rat ID4; verify sequence homology in the immunogen region if using these species in your experiments.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides a streamlined sourcing experience for IVD raw materials, including this polyclonal antibody targeting ID4 for transcription regulation and cancer research. Our platform connects diagnostic developers with validated antibody pairs, optimized monoclonal and polyclonal antibodies, bulk ancillary reagents, and rare target raw materials to accelerate your journey from concept to clinic.